[{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Equillium \/ Not Applicable"},{"orgOrder":0,"company":"Biocon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biocon \/ Not Applicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"12","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Equillium \/ Not Applicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Equillium \/ Not Applicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Equillium \/ Not Applicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocontrolled","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"12","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","graph1":"Immunology","graph2":"Phase I","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"6","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Not Applicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Decheng Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Public Offering","leadProduct":"Itolizumab","moa":"CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Equillium \/ Decheng Capital","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Decheng Capital"},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Not Applicable"},{"orgOrder":0,"company":"Equillium","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Immunology","graph2":"Preclinical","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Equillium \/ Oxford University","highestDevelopmentStatusID":"4","companyTruncated":"Equillium \/ Oxford University"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Equillium \/ Biocon Limited","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Biocon Limited"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Immunology","graph2":"Phase I","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Equillium \/ Biocon Limited","highestDevelopmentStatusID":"6","companyTruncated":"Equillium \/ Biocon Limited"},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Equillium \/ Not Applicable"},{"orgOrder":0,"company":"Biocon","sponsor":"Equillium","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Immunology","graph2":"Phase I","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biocon \/ Equillium","highestDevelopmentStatusID":"6","companyTruncated":"Biocon \/ Equillium"},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Not Applicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Not Applicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Not Applicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","graph1":"Nephrology","graph2":"Phase I","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Equillium \/ Not Applicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Itolizumab","moa":"IL-2\/IL-9\/IL-15","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Not Applicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Itolizumab","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0.16,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.16,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Ono Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Biocon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Itolizumab","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocon \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biocon \/ Not Applicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Itolizumab","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Not Applicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Itolizumab","moa":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Equillium \/ Not Applicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Itolizumab","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Not Applicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Itolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Equillium \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals for Itolizumab
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
